Claim 30% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Genetic Technologies ( (AU:GTG) ) just unveiled an update.
Genetic Technologies Limited has notified the market that 1,959,750 GTGAF warrants have lapsed following their expiry without being exercised or converted as of 6 February 2026. The cessation of these securities marginally reduces the company’s potential dilution from outstanding convertible instruments and slightly simplifies its capital structure, a routine housekeeping step that may be of interest to existing shareholders monitoring issued and potential share capital.
The most recent analyst rating on (AU:GTG) stock is a Hold with a A$0.04 price target. To see the full list of analyst forecasts on Genetic Technologies stock, see the AU:GTG Stock Forecast page.
More about Genetic Technologies
Genetic Technologies Limited, listed on the ASX under the code GTG, operates in the biotechnology sector, focusing on genetic testing and related technologies, and is part of Australia’s broader life sciences and diagnostics market.
Technical Sentiment Signal: Sell
Current Market Cap: A$5.67M
See more insights into GTG stock on TipRanks’ Stock Analysis page.